Marinus Pharmaceuticals Inc expected to post a loss of 69  cents a share - Earnings Preview

Marinus Pharmaceuticals

09/08/2022 19:33

* Marinus Pharmaceuticals Inc  MRNS.OQ   MRNS.O  is expected
to show a rise in quarterly revenue when it reports  results on
August 11. 
    * The Radnor Pennsylvania-based  company is expected to
report  a
21.5% increase in revenue to $2.315 million from $1.91 million a
year ago, according to the mean estimate from 10 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Marinus
Pharmaceuticals
Inc is for a loss of 69 cents per share. For the same quarter
last year, the company reported a loss of 65 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 10 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Marinus
Pharmaceuticals Inc is $28​, above​ its last closing price
of $5.69. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.85       -0.85      -0.52     Beat    38.8
 Dec. 31 2022  -0.72       -0.76      -0.77     Missed  -1.2
 Sep. 30 2021  -0.73       -0.73      -0.53     Beat    27.6​
 Jun. 30 2021  -0.69       -0.69      -0.65     Beat    5.3
 ​​Mar.        -0.45       -0.45      -0.74     Missed  -63.9
 31 2021                                                
 Dec. 31 2020  -0.50       -0.51      -0.55     Missed  -8.6​
 Sep. 30 2020  -0.62       -0.60      -0.51     Beat    15
 Jun. 30 2020  -0.79       -0.75      -0.64     Beat    14.8
 This summary was machine generated August 9 at 18:33 GMT.  All
figures in US dollars  unless otherwise stated